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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.07.053Background: A shortage of donors has led to the progressive expansion of criteria
for donor selection in lung transplantation. The outcome of recipients of lungs from
donors aged 50 years or older is analyzed systematically.
Methods: From March 1998 to June 2003, 49 recipients received lungs from donors
aged 50 years or older (range 50-64 years, mean 54  3 years). This group of
recipients was compared with 244 patients receiving lungs from donors aged less
than 50 years (range 7-49 years, mean 32  11 years). This study was undertaken
on all 293 patients at our institution who received Perfadex-preserved lungs
(Vitrolife, Göteborg, Sweden).
Results: Recipient age, sex, and indications for transplant did not differ significantly
between groups. Also, the percentage of the different types of transplants (bilateral
or single lung transplantation) performed was equal in both cohorts. Donor PaO2/
FIO2 ratios before lung retrieval (415  91 vs 439  113, respectively) and length
of ischemic time (347  67 minutes vs 351  84 minutes, respectively) did not
differ significantly between the older and younger donor groups. The following
posttransplant parameters were also not statistically different: first PaO2/FIO2 at
intensive care unit arrival (274  125 in the older donor group vs 253  119 in the
younger donor group, respectively), mechanical ventilation time (328  427 hours
vs 269  425 hours, respectively), and length of stay in the intensive care unit (16
 18 days vs 14  18 days, respectively). Recipient survival in the older and
younger donor groups at 30 days, 3, 6, 12, 24, and 60 months was 77%  6%, 75%
 6%, 73% 7%, 73% 7%, 68% 5%, and 68% 4% versus 86% 2%, 83%
 3%, 80%  3%, 78%  3%, 71%  4%, and 66%  4%, respectively.
Conclusions: Lung grafts from elderly donors have been considered as marginal organs
for transplantation. However, this study indicates that transplantation of lungs from
carefully selected donors aged 50 years or more may lead to similar short- and long-term
outcomes compared with lungs from younger donors. The use of lungs from elderly
donors may help to increase the number of donor organs in lung transplantation.
Lung transplantation has evolved during the past 2 decades to becomea viable treatment option for several end-stage pulmonary diseases.1Although the number of annually performed lung transplant proce-dures still increases,2 donor organ availability has become a seriousproblem, and the demand for donor lungs clearly exceeds the supply.This lack of donor organs has led to an increasing mortality of
patients on the lung transplant waiting list. Obviously, the risk of mortality by the
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TXlength of waiting time is not equal among the different
indications for lung transplantation. However, for cystic
fibrosis and interstitial pulmonary fibrosis, Hosenpud and
associates3 showed a waiting list mortality of 25% to 30%
and 40% to 45% 1 and 2 years after listing, respectively.
Several concepts to increase the number of donor organs
in lung transplantation have been mentioned. Some are still
more experimental in nature such as pulmonary xenotrans-
plantation4 or the implantation of tissue-engineered bioarti-
ficial lungs,5 whereas others have been clinically tested in
single cases such as the use of lungs from non–heart-
beating donors.6 Living-related lung or lobar transplantation
has been applied in single and specialized centers only, but
has achieved promising outcome there.7
Another concept to overcome the shortage of donor
organs is the use of lungs from so-called marginal donors,
who do not fulfill the commonly accepted lung donor cri-
teria and, thus, are usually not offered or accepted for lung
transplantation. Pierre and coworkers8 published a first ma-
jor report on their experience in using marginal donor lungs
in lung and heart-lung transplantation. They focused on the
short-term and midterm outcomes after transplantation of 63
extended donor lungs and compared those with the outcome
of 60 lung transplants with lungs from standard donors. In
that study donors were considered “marginal” when one of
the following criteria was met: (1) purulent bronchoscopic
findings, (2) PaO2less than 300 mm Hg, (3) occurrence of an
infiltrate on chest radiography, (4) active smoker (20
pack-years), or (4) donor aged 55 years or more. Although
the 30-day mortality was significantly higher in the ex-
TABLE 1. Donor characteristics
Do < 50 group
(n  244)
Do > 50 group
(n  49)
Age (y)† 32 11 (7-49) 54 3 (50-64)
Female donors (n)* 96 (39%) 27 (55%)
Cause of death (n)*
Intracerebral hemorrhage* 111 (46%) 36 (74%)
Cerebral hypoxia 20 (8%) 5 (10%)
Tumor 2 (1%) 0
Head injury* 104 (43%) 8 (16%)
Other 5 (2%) 0
Ventilation time before
harvest (d)
3.7  3.6 3.5 2.9
Final PaO2 before harvest
(mm Hg)
439 113 415 91
Total ischemic time (min) 351 84 347 67
Positive smoking history (n) 14 (6%) 5 (10%)
Do  50, Donors aged less than 50 years; Do  50, donors aged 50 years
or more.
*P  .05.
†P  .001.tended donor group compared with standard donors, donor-
920 The Journal of Thoracic and Cardiovascular Surgery ● Aprirelated death occurred in only 50% of all deaths in that
group. Thus, the authors concluded that although many
extended donor lungs will result in acceptable postoperative
function, extended donors should be carefully selected be-
cause there seems to be an increased early mortality rate in
that group of recipients.
We believe that with their first publication on ex-
tended donors, the Toronto group8 has made an important
step toward reflecting on the commonly accepted lung
donor criteria to increase the pool of transplantable donor
organs. However, in their analysis the number of patients
in the different extended criteria subgroups was small,
and statistical analysis was performed on the total num-
ber of extended donor transplants. It is possible that the
impact of purulent secretion in donor lungs, for example,
on posttransplant outcome is different from that of donor
age. Therefore, in our study we picked only 1 criterion,
donor age, for extended donors according to Pierre and
coworkers8 and systematically reviewed our experience
with transplantation of lungs from donors 50 years of age
and older.
Methods
Between March 10, 1998, and June 30, 2003, data were prospec-
tively recorded for 293 patients who underwent lung transplanta-
tion at the Hannover Thoracic Transplant Program of the Han-
TABLE 2. Recipient characteristics
Do < 50 group
(n  244)
Do > 50 group
(n  49)
Age (y) 41 13 (13-66) 42 13 (16-64)
Sex (n)
Male 136 (56%) 24 (49%)
Female 108 (44%) 25 (51%)
Indication for transplant (n)
Emphysema 82 (37%) 13 (27%)
Idiopathic pulmonary fibrosis 56 (23%) 16 (33%)
Cystic fibrosis 56 (23%) 7 (14%)
Primary pulmonary
hypertension
11 (5%) 3 (6%)
Lymphangioleiomyomatosis 3 (1%) 1 (2%)
Sarcoidosis 6 (3%) 1 (2%)
Redo-transplant for chronic
graft failure (BOS)
19 (8%) 7 (14%)
Other 11 (5%) 1 (2%)
Type of transplant (n)
Single lung transplant 42 (17%) 6 (12%)
Bilateral lung transplant 202 (83%) 43 (88%)
“High urgency” status on
waiting list (n)
56 (23%) 14 (29%)
BOS, Bronchiolitis obliterans syndrome; Do 50, donors aged less than 50
years; Do  50, donors aged 50 years or more.
P  .05.nover Medical School. This time period was chosen because we
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plant program on March 10, 1998, from the use of an intracellular-
type preservation solution (Euro-Collins) to an extracellular-type
preservation solution (Perfadex, Vitrolife, Göteborg, Sweden),9
and therefore included all patients at our program with Perfadex-
preserved lungs in this study. Data were analyzed retrospectively.
In this study patients were divided into 2 groups: donors aged less
than 50 years (Do  50) and donors aged 50 years or older (Do 
50).
All donors were assessed for acceptability for transplantation
by the retrieving lung transplant fellow or staff lung transplant
surgeon from our program. No lungs were harvested by surgeons
from other programs. Donor lungs were assessed by bronchos-
copy, laboratory work, and medical history. Macroscopic inspec-
tion of the lung was finally performed by the retrieving surgeon.
As mentioned previously, a low-potassium dextran solution (Per-
fadex) was used for lung preservation.10 Lung function before
harvest was based on the final PaO2/FIO2ratio in the operating
room. Although some donors showed initial PaO2/FIO2 ratios less
than 300, all donor lungs showed a PaO2/FIO2 ratio greater than 300
after extended donor resuscitation and specific management in-
cluding adjustment of mechanical ventilation and performance of
TABLE 3. Outcome after lung transplantation
Do < 50 group
(n  244)
Do > 50 group
(n  49)
Length of post-LTx
ventilation (hr)
269 425 328 427
Length of ICU stay (d) 14 18 16 18
Survival (%)
30 d 86 2 77 6
3 mo 83 3 75 6
6 mo 80 3 75 7
12 mo 78 3 73 7
2 y 71 4 68 5
5 y 66 4 68 4
First PaO2/FIO2 on the ICU 253 119 274 125
Cause of death after
LTx (n)
60 (25%) 15 (31%)
Acute graft failure 7 (12% of deaths) 2 (13% of deaths)
Chronic graft failure 1 (2%) 0
Sepsis/multiorgan
failure
22 (37%) 7 (47%)
Bronchial complications 6 (10%) 1 (7%)
Cardiac/hemodynamic
complications
4 (8%) 1 (7%)
Neurologic
complications
3 (5%) 2 (13%)
Gastroenterologic
complications
6 (10%) 0
Neoplasia 2 (3%) 0
Unknown 9 (15%) 2 (13%)
Do  50, Donors aged less than 50 years; Do  50, donors aged 50 years
or more; ICU, intensive care unit; LTx, lung transplantation.
P  .05.bronchoscopy. Donors with clear signs for aspiration or mucus
The Journal of Thoraciaccumulation that could not be suctioned clear as well as organs
with significant tissue traumatization or lung infiltration on radi-
ography were rejected for transplantation, regardless of the age of
the donor. Fluid accumulation was restricted to maintain euvol-
emia to avoid fluid overload and, consequently, lung edema. One
gram of prednisone was administered to the donor between the
initial contact with the donor hospital and arrival of the harvesting
surgical team.
The primary end point in this study was 1-year survival. A
second major end point was initial graft function as assessed by the
initial PaO2/FIO2ratio at arrival on the cardiothoracic intensive care
unit (ICU). Secondary end points included 30-day, 3-, 6-, 24-, and
60-month survival, donor and recipient gender and age, donor
smoking history, donor cause of death, type of transplant (single vs
bilateral lung transplant), indication for lung transplantation,
length of posttransplant mechanical ventilatory support, and dura-
tion of ICU stay. It was also recorded whether a patient had a
preoperative “high urgency” status on the waiting list because of
rapid progression of the pulmonary disease with need for intensive
care treatment or even mechanical ventilatory support.
The software package SPSS 11.0 for Windows (SPSS Inc,
Chicago, Ill) was used for statistical analysis. Group comparison
was performed with the unpaired t test for continuous variables or
the 2 test for categorical variables. The Wilcoxon and log-rank
test were used for statistical analysis of patient survival. A Cox
regression analysis was performed to test the impact of ischemic
time and donor age on posttransplant survival days. Data are
presented as means  SD.
Results
Of the 293 patients included in this study, 244 patients
received lungs from donors aged less than 50 years (donor
age: 32  11 years, range: 7-49 years). Forty-nine patients
underwent transplantation with lungs from donors aged 50
%
(Log rank: ns)
: Do<50
- - - : Do>50
Figure 1. Survival during the first year after lung transplantation
in group comparison. (Do < 50, donors aged less than 50 years;
Do > 50, donors aged 50 years or more.)years or less (donor age: 54  3 years, range: 50-64 years).
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tween the 2 groups. The mean donor age was significantly
older in the group of elderly donors (P  .001). The length
of mechanical ventilation before harvest did not differ sig-
nificantly among groups with 3.5 2.9 days in the Do 50
cohort and 3.7  3.6 days in the Do  50 cohort. In
addition, donor pulmonary function before lung retrieval as
assessed by PaO2/FIO2at mechanical ventilation with an FIO2
of 1.0 and a positive end-expiratory pressure of 5 cm H2O
was also not statistically different among groups (Do  50:
415  91 vs Do  50: 439  113). With regard to donor
cause of death, a significant difference was seen between
groups. It is interesting that the occurrence of intracerebral
hemorrhage apparently becomes the predominant cause of
donor death with increasing donor age. In the Do  50
group, 74% of donors died of intracerebral hemorrhage
versus 46% of donors in the Do  50 group. However, in
the younger donor cohort 43% died of head injury, whereas
in the elderly group of donors only 16% experienced head
injury. With respect to smoking history, only incomplete or
no data are often available at the time of multiorgan donor
allocation. Therefore, in this study the individual smoking
history was comprehensible for only 22% of patients at the
time of organ retrieval. In consideration of this limitation, a
positive smoking history was known for 10% (n  5/49) of
patients in the Do 50 and for 6% (n 14/243) of patients
in the Do  50 group. The total length of graft ischemic
TABLE 4. Outcome after lung transplantation by different
Do 50-
(n 
Length of post-LTx ventilation (hr) 364
Length of ICU stay (d) 18
Survival (%)
30 d 90
3 mo 81
6 mo 71
12 mo 71
First PaO2/FIO2 on the ICU 282
Best FEV1 (% of predicted FEV1) 73 
Cause of death after LTx (n) 10 (3
Acute graft failure 1 (11% of
Chronic graft failure 1 (11
Sepsis/multiorgan failure 4 (44
Bronchial complications 1 (11
Cardiac/hemodynamic complications 1 (11
Neurologic complications 1 (11
Gastroenterologic complications 0
Neoplasia 0
Unknown 1 (11
Do  50, Donors aged 50 years or more; LTx, lung transplantation; ICU, i
P  .05.time between groups also was not statistically different with
922 The Journal of Thoracic and Cardiovascular Surgery ● Apri347  67 minutes in the Do  50 group and 351  84
minutes in the Do  50 group.
There were 48 single lung transplants and 245 bilateral
lung transplants performed in the total cohort. The number
of single lung and bilateral lung transplant procedures per-
formed in the Do  50 group was n  6 (12%) and n  43
(88%), respectively, and n  42 (17%) and n  202 (83%)
in the Do  50 group, respectively. Table 2 shows recipient
characteristics including the indications for lung transplan-
tation.
Table 3 summarizes the outcome after lung transplanta-
tion among groups regarding several end points. The 30-
day, 3-, 6-, 24-, and 60-month survival was 77%  6%,
75%  6%, 73%  7%, 68%  5%, and 68%  4% in the
Do  50 group compared with 86%  2%, 83%  3%,
80%  3%, 71%  4%, and 66%  4% in the Do  50
group, respectively, which did not show statistical differ-
ences. The primary end point, 1-year survival, did not show
a significant difference between groups, with 73%  7%
(Do 50) and 78% 3% (Do 50) (Figure 1). The initial
graft function as assessed by the first PaO2/FIO2at arrival to
the ICU was not different between groups with 274  125
and 253  119, respectively. The different causes of death
in both groups are also summarized in Table 3.
In addition, a subanalysis on the Do  50 group was
performed with regard to age. Therefore, patients were
subdivided into 3 groups: (1) donors aged 50 to 54 years, (2)
subgroups in the elderly donor cohort (Do > 50)
Do 55-59 y
(n  12)
Do > 59 y
(n  6)
307 452 303  221
14 19 7  9
82  3 75  3
73  2 75  3
73  2 75  3
73  2 75  3
261 151 262  113
80 18 87  32
4 (36%) 1 (25%)
hs) 1 (25% of deaths) 0
0 0
3 (75%) 0
0 0
0 0
0 1 (100%)
0 0
0 0
0 0
ve care unit; FEV1, forced expiratory volume in 1 second.age
54 y
31)
450
20
2
2
1
1
138
22
2%)
deat
%)
%)
%)
%)
%)
%)
ntensidonors aged 55 to 59 years, and (3) donors aged more than
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than 50 years have frequently been considered as extended
donors, it is possible that the clinically relevant cutoff point
for donor age is more than 50 years. However, as shown in
Table 4, the clinical outcome was not statistically different
among the 3 subgroups.
A significant number of the “high urgency” candidates,
which are indicated in Table 2, required pretransplant me-
chanical ventilatory support before lung transplantation be-
cause of rapid deterioration of their lung function. This,
however, is a widely known risk factor for posttransplant
survival, as repeatedly underlined in the annual report of the
International Society for Heart and Lung Transplantation
(ISHLT) registry.11 In previous data analyses at our insti-
tution we also showed that a pretransplant “high urgency”
status on the waiting list significantly increases the risk for
posttransplant mortality. Therefore, in a second subanalysis
we excluded all “high urgency” patients in both study
groups and found a 1-year survival of 74%  8% in the Do
 50 group and 78%  3% in the Do  50 cohort (no
significant difference), which also was not different from
the overall survival in groups. The percentage of “high
urgency” candidates was 23% in the younger donor group
and even higher in the elderly donor cohort (29%) (Table 2).
It was reported in the literature that elderly lung grafts
may show diminished “functional reserve,” which could
lead to poor posttransplant graft function.12 This is certainly
biologically valid; however, it has never been shown in lung
function studies in elderly grafts after transplantation. We
compared the portions of the predicted 1-second forced
expiratory volumes (FEV1) in both groups at 2 and 4 weeks
as well as 3, 6, 9, and 12 months after lung transplantation
and found that the 2 curves were almost identical among
groups. Furthermore, we compared the best FEV1 values in
groups during the first year after transplantation. Once
again, the results were not statistically different among
groups, with 79% 22% in the Do  50 group and 76%
22% of predicted FEV1 in the elderly donor group (P  .2).
These data indicate that, especially in the very early peri-
operative period, the functional reserve of the elderly grafts
was not diminished in comparison with that of the grafts in
the Do  50 group.
Discussion
The imbalance between the number of patients listed for a
lung transplantation and the number of available donor
organs has led to extended waiting times and, ultimately, to
a significant mortality on the waiting list.13 Consequently,
novel strategies have been discussed and partially intro-
duced into clinical lung transplantation to increase the num-
ber of suitable donor organs. A first and reasonable step was
the idea of extending the currently accepted criteria for
donor selection. Many programs have begun to use mar-
The Journal of Thoraciginal or extended donors after reports suggesting equivalent
outcomes. The Toronto group8 published a retrospective
review on 128 consecutive lung and heart/lung transplants,
of which 51% were grafts retrieved from “extended do-
nors.” In that study by Pierre and colleagues,8 donors were
considered “extended” if one of the following criteria was
met: age more than 55 years, smoking history more than 20
pack-years, presence of chest radiographic film infiltrate,
PaO2 less than 300 mm Hg before lung retrieval, or purulent
secretions on pre-retrieval bronchoscopy. They concluded
that caution should be exercised in the use of certain ex-
tended donor lungs, because there seems to be an increased
early mortality rate in that group of recipients, although
many extended donor lungs will result in acceptable post-
operative function. This particular finding underlines the
need for further studies to clearly identify the new border-
line to which donor lungs can be accepted for transplanta-
tion with a reasonable chance for successful outcome and
below which, on the other hand, lungs should probably not
be accepted for transplantation. This study further suggests
different donor variables such as donor age, bronchoscopic
and radiography findings, time of ventilation before organ
retrieval, and smoking history, each of which can identify a
donor as a “marginal” donor and could possibly be extended
to increase the number of transplantable donor organs. It has
become a novel standard that the ISHLT discusses the issue
of redefining currently accepted lung donor criteria and the
concept of using marginal donor organs for selected recip-
ients in a main session at the Society’s annual meeting. In a
consensus report from the Pulmonary Council of the
ISHLT, Orens and associates12 extendedly reviewed the
currently accepted lung transplant donor acceptability cri-
teria. Therefore, they reviewed the evidence in the literature
regarding 13 major risk factors for outcome after lung
transplantation. With regard to the impact of donor age on
lung transplant outcome, they repeatedly underlined a pos-
sible negative interaction between donor age and graft isch-
emic time.12 Novick and associates14 found that lung donor
age less than 10 years or more than 50 years may be
associated with an increase in posttransplant mortality ac-
cording to data derived from patients who were reported to
the United Network for Organ Sharing (UNOS) and ISHLT
registry between 1987 and 1997. Therefore, in our study we
chose 50 years as the donor age limit between both study
groups. The negative interaction between donor age and
ischemic time as described by Novick and colleagues, how-
ever, could not be confirmed in a large, recently published
multivariate analysis by the Eurotransplant International
Foundation in Leiden (The Netherlands) and coinvestigators
on 590 consecutive lung transplants, which were performed
between 1997 and 1999 at 21 Eurotransplant centers.15
Certainly, the largest data set on patient outcome after lung
transplantation is the ISHLT registry.2 In the 18th report on
c and Cardiovascular Surgery ● Volume 129, Number 4 923
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annually performed lung transplant procedures and donor
age was described. Odds ratios changed from 0.57, 1.16, to
2.37 in centers performing 55, 30, and 5 lung transplants per
year, respectively, with a donor age of 60 years.16 This
possible association between center lung transplant volume
and lung survival, however, was not supported by data from
the Eurotransplant analysis.15
Except for reports on singular cases or small patient co-
horts, the literature does not provide sufficient evidence regard-
ing the impact of donor age on lung transplantation outcome.
As summarized in the ISHLT Pulmonary Council report,
smaller studies have not shown a survival disadvantage with
the use of elderly donors,17,18 but larger registry studies such as
the ISHLT registry report or the study by Novick and associ-
ates have indicated a negative effect on survival, particularly
when combined with increased graft ischemic time.14,16
In 1998, a significant change in clinical lung transplantation
occurred with the introduction by us and others9,10 of Perfadex
preservation solution, which is based on an extracellular-type
low-potassium dextran solution. Since that time, increasing
numbers of lung transplant centers throughout the world have
switched their lung-preservation strategies from intracellular-
type high-potassium solutions to the use of Perfadex. By im-
proving lung tissue preservation and, ultimately, posttransplant
lung graft function, prolonged ischemic tolerance in human
lungs was also achieved. This point is important because the
majority of patients included in the study by Novick and
colleagues14 received lungs that were not preserved with high-
potassium–based preservation solutions. Also, a significant
portion of cases included in the ISHLT registry until today
have not received low-potassium–based preserved lungs. As-
suming that the concept of diminished “functional reserve” in
elderly donor lungs is valid, this fact may explain why a
negative association between donor age and ischemic time was
repeatedly shown in these analyses. This study is the first to
focus specifically on the impact of lung donor age on post-
transplant outcome in the low-potassium–based lung preser-
vation era. We were not able to show differences in pulmonary
function tests in our patients. In the early perioperative period
and during the first year after transplantation, the FEV1 and
best FEV1 measures between groups were almost identical.
Thus, our study does not underline the theoretically reported
diminished “functional reserve” in elderly lung grafts. This
finding could further be an effect of better lung preservation
with low-potassium dextran, in that the lower functional re-
serve in elderly lung grafts is better preserved.
From the molecular standpoint, the discussion around the
use of elderly donor lungs for transplantation should cer-
tainly include the different mechanisms of brain death. As
shown in this study the majority of donors in the elderly
cohort died of cerebrovascular accidents, whereas more
donors in the younger cohort died of head injury. The type
924 The Journal of Thoracic and Cardiovascular Surgery ● Apriof brain death and the neurohumoral and biochemical
changes that occur with brain death are different in a patient
whose death was caused by trauma and a patient whose
death was the result of cerebrovascular accident. It is pos-
sible that the cause of brain death will become even more
relevant with increasing use of elderly donor organs in the
future. The relationships between the outcome after trans-
plantation of elderly lungs and the mechanisms of brain
death should be investigated in future work and cannot be
explained in this study.
In summary, there is still intense debate ongoing about
the impact of donor age on outcome after lung transplanta-
tion. We found that the short- and long-term outcomes are
similar after transplantation of lungs from donors 50 years
of age and older compared with that after transplantation of
lungs from younger donors. It is important to note that all
lungs in this study were preserved with a low-potassium–
based preservation solution (Perfadex). On the basis of the
findings in this study, we recommend that acceptability
criteria for donor lungs should be reassessed with regard to
“elderly” donor organs. It is not clear whether older donor
lungs may have beneficial or detrimental effects on overall
outcome after lung transplantation. A beneficial effect could
be a decline in immune function leading to lower suscepti-
bility to rejection. A detrimental effect could be reduced
lung function because of subclinical emphysematous
changes or an increased susceptibility to certain cancers.
Because this is not clear, lungs from elderly donors should
only be transplanted after careful selection. No other eval-
uation parameter except for donor age should be out of
“traditional limits” when elderly organs are evaluated for
lung transplantation.
We thank Mrs. Petra Oppelt for data review and analysis as a
professional biostatistician. Mrs. Kerstin Meyer, MS, has signifi-
cantly contributed to collecting and analyzing data in this study.
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